Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cost-effective statins?

This article was originally published in The Tan Sheet

Executive Summary

"Statin therapy should be considered routinely for people across a wider age range and at lower risk of vascular disease than is currently the case," a BMJ online first study published Nov. 10 concludes. At current UK prices, a 40 mg dose of the drug "is likely to be cost saving, or would cost less than £2,500 per life year gained, for people with an annual risk of major vascular events of 1% or more," according to results from the Heart Protection Study Collaborative Group. In the UK, statin treatment is currently recommended for those who have an estimated 10-year risk of a cardiovascular event of 20% or more, the study notes. The trial evaluated 20,356 men and women with coronary disease, other occlusive arterial disease or diabetes in 69 hospitals in the UK. A model was developed to estimate lifetime risks of vascular events and costs of treatment and hospital admissions in the country...

You may also be interested in...



Statins Cost-Effective For High-Risk Patients – JAMA Study

Statins appear to be cost-effective for high-risk, primary-prevention patients who have an absolute 10-year coronary heart disease-event rate of higher than 20%, according to a meta-analysis in the Nov. 27 Archive of Internal Medicine, a JAMA journal

Changing Of The Guard At Merck KGaA With Garijo Succeeding Oschmann As CEO

The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.

FDA Talks Tough On Complete Response Extensions

The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel